Xiaohui Wei

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

Kenneth Kalunian, Joan T. Merrill, Romeo Maciuca et al. · Annals of the Rheumatic Diseases · 2015 · 339 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Paul Rutgeerts, Richard N. Fedorak, Daan W. Hommes et al. · Gut · 2012 · 150 citations · Full text

Medicine, Immunology, Pharmacology +17

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)

Shabnam Naseer, Edward A. Weinstein, Daniel B. Rubin et al. · Clinical Infectious Diseases · 2020 · 53 citations

Pharmacy, Infectious Diseases, Pharmacology +16

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Rebecca B. Klisovic, William Blum, Xiaohui Wei et al. · Clinical Cancer Research · 2008 · 39 citations · Full text

Medicine, Oncology, Pharmacology +14

Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report

yunmei Wang, Shuguang Liu, Xiaohui Wei et al. · OncoTargets and Therapy · 2018 · 15 citations · Full text

Medicine, Oncology, Pharmacotherapy +17